The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://zubairxfmx628394.pages10.com/retatrutide-vs-tirzepatide-a-comparative-analysis-74115373